Evaluation of the Efficacy and Safety of an Intensified Strategy of Intratonsillar Immunotherapy (ITIT) for Allergic Rhinitis: A Multicenter, Randomized, Double-blind, Controlled Trial

Exclusion Criteria

• •1. Allergic to the excipients of Arrogel (aluminum hydroxide) or the rescue medication epinephrine
• •2. Suffering from respiratory system diseases other than stable asthma
• •3. Pulmonary dysfunction (NYHA grade II or above, or FeV1 \< 70%) or having irreversible pathological changes in the reactive organs such as emphysema or bronchiectasis
• •4. Severe acute or chronic diseases (including malignant diseases), inflammation and fever
• •5. Multiple sclerosis
• •6. Immune system diseases (autoimmune diseases, immune diseases caused by antigen-antibody complexes, immune deficiencies, etc.)
• •7. Active pulmonary tuberculosis
• •8. Severe mental disorders
• •9. Obvious cardiac dysfunction
• •10. Patients who have received immunotherapy within the last 1 years (subcutaneous injection or sublingual administration of allergen-specific immunotherapy, etc.)
• •11. Patients who used experimental drugs or participated in other clinical studies within 30 days before treatment
• •12. Patients who received IgE monoclonal antibody (mAb) treatment in the past 4 months
• •13. Patients taking beta-blockers
• •14. Patients who have insufficient understanding of the trial
• •15. Patients whose age is not between 5 years old and 65 years old
• •16. Patients who are pregnant or breastfeeding during the study period, or have plans to get pregnant
• •17. Patients who cannot undergo tonsil injection due to acute or chronic tonsillitis, small tonsils, previous tonsillectomy, overly sensitive pharyngeal reflex and inability to cooperate with treatment
• •18. Patients with aphthous stomatitis